Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
11273 studies found for:    NCI
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Not yet recruiting Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Conditions: Adenoid Cystic Carcinoma;   Adnexal Carcinoma;   Apocrine Carcinoma;   Eccrine Porocarcinoma;   Extraocular Cutaneous Sebaceous Carcinoma;   Hidradenocarcinoma;   Keratoacanthoma;   Malignant Sweat Gland Neoplasm;   Merkel Cell Carcinoma;   Microcystic Adnexal Carcinoma;   NK-Cell Lymphoma, Unclassifiable;   Non-Melanomatous Lesion;   Paget Disease;   Papillary Adenocarcinoma;   Primary Cutaneous Mucinous Carcinoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory T-Cell Non-Hodgkin Lymphoma;   Sezary Syndrome;   Signet Ring Cell Carcinoma;   Skin Basal Cell Carcinoma;   Skin Basosquamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Spiradenocarcinoma;   Squamous Cell Carcinoma of Unknown Primary Origin;   Stage III Skin Cancer;   Stage IV Skin Cancer;   Sweat Gland Carcinoma;   Trichilemmocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Talimogene Laherparepvec
2 Not yet recruiting Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
Condition: Recurrent Glioblastoma
Interventions: Biological: Bevacizumab;   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib
3 Not yet recruiting Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
Conditions: EGFR Activating Mutation;   EGFR NP_005219.2:p.T790M;   Metastatic Malignant Neoplasm in the Brain;   Non-Small Cell Lung Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma
Interventions: Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Osimertinib
4 Not yet recruiting Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
Condition: Cirrhosis
Interventions: Other: Laboratory Biomarker Analysis;   Other: Placebo;   Drug: Simvastatin
5 Not yet recruiting Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
Conditions: Recurrent Melanoma;   Stage III Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Biological: Talimogene Laherparepvec
6 Not yet recruiting Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma
Condition: Colorectal Adenoma
Interventions: Drug: Aspirin;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Questionnaire Administration
7 Not yet recruiting Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
Conditions: Attenuated Familial Adenomatous Polyposis;   Familial Adenomatous Polyposis
Interventions: Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis
8 Recruiting Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Stage 0 Breast Cancer;   Stage I Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
9 Not yet recruiting Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure
Condition: Previously Treated Myelodysplastic Syndrome
Interventions: Drug: Entinostat;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
10 Not yet recruiting Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
Conditions: Leiomyosarcoma;   Liposarcoma;   Sarcoma Differentiation Score 2;   Sarcoma Differentiation Score 3;   Stage IA Soft Tissue Sarcoma;   Stage IB Soft Tissue Sarcoma;   Stage IIA Soft Tissue Sarcoma;   Stage IIB Soft Tissue Sarcoma;   Undifferentiated Pleomorphic Sarcoma
Interventions: Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Biological: Talimogene Laherparepvec
11 Not yet recruiting Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Recurrent Cervical Carcinoma;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Interventions: Drug: Atezolizumab;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis
12 Recruiting Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
Conditions: Rectal Adenocarcinoma;   Stage II Rectal Cancer;   Stage III Rectal Cancer
Interventions: Drug: Capecitabine;   Drug: Fluorouracil;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Drug: Veliparib
13 Not yet recruiting ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment
Conditions: Oral Cavity Neoplasm;   Oropharyngeal Neoplasm;   Stage I Oral Cavity Squamous Cell Carcinoma;   Stage I Oropharyngeal Squamous Cell Carcinoma;   Stage II Oral Cavity Squamous Cell Carcinoma;   Stage II Oropharyngeal Squamous Cell Carcinoma;   Stage III Oral Cavity Squamous Cell Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Oral Cavity Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Oral Cavity Squamous Cell Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet;   Other: Pharmacological Study;   Other: Placebo
14 Not yet recruiting Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability
Conditions: Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Microsatellite Instability;   Stage IIIA Colon Cancer;   Stage IIIB Colon Cancer;   Stage IIIC Colon Cancer
Interventions: Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
15 Not yet recruiting Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
Condition: Small Cell Lung Carcinoma
Interventions: Drug: Carboplatin;   Drug: Cediranib Maleate;   Drug: Cisplatin;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib
16 Recruiting Panobinostat in Treating Younger Patients With Progressive Diffuse Intrinsic Pontine Glioma
Condition: Diffuse Intrinsic Pontine Glioma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Panobinostat;   Other: Pharmacological Study
17 Not yet recruiting Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Metastatic Solid Neoplasm;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Triple-Negative Breast Carcinoma;   Unresectable Solid Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Onalespib;   Other: Pharmacological Study
18 Not yet recruiting Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
Conditions: Pancreatic Neuroendocrine Tumor G1;   Pancreatic Neuroendocrine Tumor G2;   Recurrent Pancreatic Neuroendocrine Carcinoma
Intervention: Drug: Sapanisertib
19 Not yet recruiting Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation;   Prostate Carcinoma Metastatic in the Bone;   Prostate Small Cell Carcinoma;   Stage IV Prostate Adenocarcinoma
Interventions: Drug: Cediranib;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib
20 Recruiting FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
Conditions: Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer
Interventions: Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Veliparib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.